What happened with TVRD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tvardi Therapeutics is a clinical-stage drug developer focused on inflammatory diseases and diseases involving abnormal cell growth, including cancer. Its candidates target STAT3, a protein involved in these diseases. The business centers on TTI-101, being tested for hepatocellular carcinoma, the main form of liver cancer, and TTI-109, a related candidate designed to improve drug delivery and tolerability. TTI-109 is in an early trial in healthy volunteers. A TTI-101 trial in idiopathic pulmonary fibrosis did not meet its goals.
No product is approved for sale, and the company has generated no revenue. It has funded development through investor capital and its merger with Cara, and needs additional funding to continue its planned work. Future revenue could come from selling approved drugs or payments from biopharmaceutical partners under licensing or collaboration agreements. Drug sales require successful further trials and regulatory approval, and would also depend on insurance coverage and reimbursement.
Tvardi retains exclusive worldwide rights to its candidates, partly through licenses from Baylor College of Medicine that carry development obligations and royalties. TTI-101 lacks patents protecting the compound itself; its patent protection instead covers particular uses, manufacturing and formulations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tvardi's prospects hinge on TTI-101 results in liver cancer (HCC), including combinations with Roche's atezolizumab and bevacizumab, whose established regimen also sets a competitive benchmark.
Purple Biotech's cancer candidate NT219 inhibits STAT3, competing with Tvardi's approach to developing cancer drugs around the same target. Further NT219 development depends on a partner or sufficient investment, making funding or partnership news the key sign that this rival can advance.
Tyra Biosciences is developing TYRA-430, an oral small-molecule drug for FGF19-positive liver cancer (HCC), overlapping with patients Tvardi targets with TTI-101. Progress in TYRA-430 would show how competition is developing in that specific patient group.
Moleculin Biotech's WP1066 portfolio competes with Tvardi in STAT3-directed drug development, rather than directly matching its liver-cancer focus. Moleculin's disclosed clinical work centers on Annamycin, so WP1066-specific progress is more relevant to this tie than its main trial news.
Merck's pembrolizumab has a dual role for Tvardi: it competes as a liver-cancer (HCC) treatment and is also combined with TTI-101 in one arm of Tvardi's liver-cancer trial.
AstraZeneca's established durvalumab-plus-tremelimumab treatment for liver cancer (HCC) sets a competitive benchmark for Tvardi's TTI-101 development.
Bristol Myers Squibb's nivolumab-plus-ipilimumab treatment competes for liver-cancer (HCC) patients in the market Tvardi aims to enter with TTI-101.
Merck & Co., Inc. earningsMRK
Merck’s report can show how its pembrolizumab business is doing; the drug competes in liver cancer and is also paired with TTI-101 in one of Tvardi’s trial arms.
Look for Merck’s disclosures on pembrolizumab and related cancer treatment business. Continued strength would mean Tvardi faces an established treatment while needing to show that adding TTI-101 has value; weakness could change the competitive backdrop, but would not establish TTI-101’s efficacy.
Tyra Biosciences, Inc. earningsTYRA
If Tyra Biosciences reports on TYRA-430, its report will show how another oral drug is progressing in an HCC patient group that overlaps with Tvardi’s target population.
Check whether Tyra reports clinical progress for TYRA-430 in FGF19-positive HCC. Clear progress would put another oral candidate on a path to compete for this subset of patients with Tvardi’s TTI-101; no progress would make that pipeline challenge less immediate, not validate TTI-101.
Tvardi Therapeutics, Inc. earningsThis company
Tvardi Therapeutics’ report will show how much cash its trials and research used, and whether its available funds can keep those programs moving.
Read cash used in operations and cash plus short-term investments alongside research spending on TTI-101 and TTI-109. Slower cash use with continued program spending would leave more time to advance trials; faster use or constrained spending would mean greater financing pressure and possible delays to development.
Purple Biotech Ltd. earningsPPBT
If Purple Biotech’s report shows funding or a partner for NT219, it will indicate whether another STAT3-targeting cancer program can advance alongside Tvardi’s approach.
Look for funding or a partner for NT219 and whether Purple Biotech says it can continue development. Support would keep a STAT3-targeting rival moving; without it, NT219 may be constrained and this direct competitive threat less immediate, while Tvardi’s own efficacy and funding remain separate questions.
